Phase 1 Randomized Double-Blind Placebo-Controlled Trial of RBD7007 in Complement-Mediated Diseases in Healthy Participants

The primary objective of this phase 1, randomized, double-blind, single-center, placebo-controlled trial is to assess the **safety** and **tolerability** of RBD7007 in healthy participants. This evaluation is crucial for determining the initial safety profile of RBD7007, which is intended for use in treating **complement-mediated diseases**. Understanding the safety and tolerability in a healthy population is a foundational step in the clinical development process, ensuring that the investigational product does not pose undue risk before further studies in patients with the target condition.

The clinical trial involves participants diagnosed with **complement-mediated diseases**. The study population includes both male and female subjects, with an age range of 18 to 65 years. The total number of participants has not been disclosed by the sponsor. The trial population was selected without targeting any vulnerable groups. Participants are expected to be in general good health, aside from their specific medical condition. No specific lifestyle considerations such as diet, physical activity, or habits have been highlighted as part of the study criteria. Key inclusion or exclusion criteria have not been provided.

This clinical trial is a **phase 1**, randomized, double-blind, single-center, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD7007 in healthy participants. The trial targets **complement-mediated diseases** and is scheduled to commence recruitment on November 1, 2024, with an estimated completion date of January 1, 2026. The study will involve a series of structured visits, beginning with an inclusion visit where participants will undergo screening to determine eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to receive either the investigational product or a placebo in a double-blind manner, ensuring that neither the participants nor the investigators are aware of the group assignments.

Throughout the trial, participants will attend regular follow-up visits to monitor their health status, assess the investigational product's effects, and collect data on pharmacokinetics and pharmacodynamics. These visits are crucial for ensuring participant safety and the integrity of the data collected. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes and any long-term effects of the investigational product. The expected duration of participant involvement will vary depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict regulatory and ethical guidelines to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is November 1, 2024, with an anticipated end date of January 1, 2026. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant biomarkers or symptom improvement. The schedule for measuring and collecting data is typically aligned with the trial's protocol, ensuring systematic and consistent data collection throughout the study duration. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's findings will contribute to the understanding of the investigational product's efficacy profile, guiding future research phases.